Researchers at MIT have found that changing how much tumour-targeting material an experimental vaccine carries can make a substantial difference to the immune response it produces. In mice, vaccines displaying more of the chosen target triggered stronger immune responses and helped suppress tumour growth. Advanced Healthcare Materials (source, opens in new tab)Advanced Healthcare MaterialsEngineering Antigen Density on M13 Bacteriophage for Personalized NanovaccineOpen source (opens in new tab)
The approach uses a modified bacteriophage, a virus that normally infects bacteria, as a carrier for small fragments of proteins known as antigens. These fragments help the immune system recognise a particular target. By adjusting how densely the antigens cover the carrier, researchers can influence how strongly immune cells respond.
In one experiment involving a mouse model of colorectal cancer, the proportion of immune cells recognising the selected tumour target increased from approximately 1.1% with a lower-density vaccine to 7.4% with a higher-density version. Mice receiving the higher-density vaccine also showed reduced tumour growth and longer survival after tumour cells were introduced.
There is an important distinction: the mice were vaccinated before they received tumour cells. The study therefore tested protection against a subsequent tumour challenge, not whether the vaccine could treat an existing cancer.
The research, published in Advanced Healthcare Materials, examined a vaccine platform built around M13 bacteriophages. These viruses have a long, protein-coated structure that researchers can modify to display different antigens. In this study, they adjusted the proportion of coat proteins carrying an antigen from approximately 6% to 70.4%.
The researchers first investigated how antigen density affected the response of CD8+ T cells, immune cells capable of recognising and killing cells displaying specific targets. Higher-density vaccine formulations produced stronger antigen-specific responses than lower-density versions.
They then tested the approach using ADPGK, a neoantigen associated with the MC-38 mouse colorectal-cancer model. Neoantigens arise from changes in cancer cells and can provide targets that distinguish tumour cells from normal cells. The higher-density ADPGK formulation produced a larger population of T cells recognising this particular target.
Following vaccination, the mice were challenged with MC-38 tumour cells. Those given the higher-density ADPGK vaccine showed suppressed tumour growth and longer median survival than the comparison groups. Together, the immune and tumour findings suggest that antigen density is an important design variable for this experimental platform.
The broader possibility is that researchers could adapt the same carrier to display different tumour targets, adjusting their density to influence the immune response. But the study has not demonstrated a personalised vaccine for patients, nor established whether the approach can safely and effectively treat existing cancers.
For now, the finding is about vaccine design rather than a new cancer treatment: in these mouse experiments, how an antigen was displayed mattered alongside which antigen was selected.
- Advanced Healthcare Materials · Peer-reviewed studyEngineering Antigen Density on M13 Bacteriophage for Personalized Nanovaccineonlinelibrary.wiley.com · opens in new tab
